Phase 3 trials examining new treatments for metastatic hormone-sensitive prostate cancer (mHSPC) can take up to a decade to complete when overall survival (OS) is used as the primary end point due to the large trial sizes and extended follow-up periods required of OS measurement. While new research, including the CHAARTED trial, has aimed to expand the survival rates of patients with mHSPC, the 5-year OS rate of metastatic prostate cancer remains at 30%. ...